Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey

Author:

DiStefano Michael J.12ORCID,Alexander G. Caleb345,Polsky Daniel167,Anderson Gerard F.15

Affiliation:

1. Department of Health Policy & Management Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA

2. Berman Institute of Bioethics Johns Hopkins University Baltimore Maryland USA

3. Center for Drug Safety and Effectiveness Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA

4. Department of Epidemiology Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA

5. Division of General Internal Medicine Johns Hopkins Medicine Baltimore Maryland USA

6. Carey Business School Johns Hopkins University Baltimore Maryland USA

7. Hopkins Business of Health Initiative Johns Hopkins University Baltimore Maryland USA

Funder

Arnold Ventures

Publisher

Wiley

Subject

Geriatrics and Gerontology

Reference19 articles.

1. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

2. The amyloid hypothesis on trial

3. Revisiting FDA Approval of Aducanumab

4. FeuersteinA HerperM GardeD.Inside ‘Project Onyx’: How Biogen used an FDA back channel to win approval of its polarizing Alzheimer's drug. Stathttps://www.statnews.com/2021/06/29/biogen-fda-alzheimers-drug-approval-aduhelm-project-onyx/. Published 2021. Accessed October 5 2021.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3